Q/C Technologies, Inc. has taken a significant step by entering into an Omnibus Amendment Agreement with PharmaCyte Biotech, Inc. This agreement, filed on November 20, 2026, modifies the rights of security holders, particularly concerning the Series G and Series H Preferred Stocks. This development is crucial for the company as it seeks to strengthen its financial position and enhance its operational strategies in the competitive field of diagnostic substances.
Q/C Technologies, Inc. operates under the SIC classification of 2835, which pertains to In Vitro & In Vivo Diagnostic Substances. The company is listed on the Nasdaq under the ticker QCLS. Recent filings include a quarterly report on November 16, 2026, and another 8-K on November 13, 2026, indicating its active engagement in financial reporting and compliance.
The Omnibus Amendment Agreement allows PharmaCyte, which holds a majority of the Series G and Series H Preferred Stocks, to amend the terms of these securities. Specifically, the agreement involves filing amendments to the Series G and Series H Certificates of Designations, which detail the rights and privileges associated with these preferred stocks. The amendments include changes to the beneficial ownership limitations and other provisions that govern these securities.
This move may affect existing and potential investors, as it alters the landscape of shareholder rights and could influence the company's stock performance. By modifying these agreements, Q/C Technologies aims to enhance its flexibility in capital management and align its financial strategies with the evolving market conditions.
Looking ahead, the filing does not specify the next steps following this agreement. However, the company may continue to engage with its investors and stakeholders to communicate the implications of these changes and how they will support its growth objectives.
Read Next
ONE Nuclear Energy settles consulting fees with stock issuance
HCW Biologics delays stockholder vote amid quorum issues
bioAffinity Technologies amends share structure in 8-K filing
VisionWave amends sponsorship deal with Hen Basketball Haifa Club
Apimeds Pharmaceuticals Amends Agreement with FreeT Inc.
Fortitude Gold Corp sells 2.8 million shares to investor










